Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Molecular epidemiology of Marek's disease virus in central Pennsylvania, USA.

Bell AS, Kennedy DA, Jones MJ, Cairns CL, Pandey U, Dunn PA, Szpara ML, Read AF.

Virus Evol. 2019 Apr 23;5(1):vey042. doi: 10.1093/ve/vey042. eCollection 2019 Jan.

2.

Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance.

Kennedy DA, Read AF.

Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):12878-12886. doi: 10.1073/pnas.1717159115. Epub 2018 Dec 17.

3.

Effects of multiple sources of genetic drift on pathogen variation within hosts.

Kennedy DA, Dwyer G.

PLoS Biol. 2018 Mar 28;16(3):e2004444. doi: 10.1371/journal.pbio.2004444. eCollection 2018 Mar.

4.

Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.

Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Uttarwar M, Lee SY, Ren H, Kennedy DA, Shustov AR.

Blood. 2018 May 10;131(19):2120-2124. doi: 10.1182/blood-2017-12-821009. Epub 2018 Mar 5.

5.

Modeling Marek's disease virus transmission: A framework for evaluating the impact of farming practices and evolution.

Kennedy DA, Dunn PA, Read AF.

Epidemics. 2018 Jun;23:85-95. doi: 10.1016/j.epidem.2018.01.001. Epub 2018 Jan 10.

6.

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.

Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Fenton K, Huebner D, Pinelli JM, Kennedy DA, Shustov A.

Blood. 2017 Dec 21;130(25):2709-2717. doi: 10.1182/blood-2017-05-780049. Epub 2017 Oct 3. Erratum in: Blood. 2018 Jul 26;132(4):458-459.

7.

Industry-Wide Surveillance of Marek's Disease Virus on Commercial Poultry Farms.

Kennedy DA, Cairns C, Jones MJ, Bell AS, Salathé RM, Baigent SJ, Nair VK, Dunn PA, Read AF.

Avian Dis. 2017 Jun;61(2):153-164. doi: 10.1637/11525-110216-Reg.1.

8.

Why does drug resistance readily evolve but vaccine resistance does not?

Kennedy DA, Read AF.

Proc Biol Sci. 2017 Mar 29;284(1851). pii: 20162562. doi: 10.1098/rspb.2016.2562. Review.

9.

DNA from Dust: Comparative Genomics of Large DNA Viruses in Field Surveillance Samples.

Pandey U, Bell AS, Renner DW, Kennedy DA, Shreve JT, Cairns CL, Jones MJ, Dunn PA, Read AF, Szpara ML.

mSphere. 2016 Oct 5;1(5). pii: e00132-16. eCollection 2016 Sep-Oct.

10.

Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting.

Gopal AK, Pro B, Connors JM, Younes A, Engert A, Shustov AR, Chi X, Larsen EK, Kennedy DA, Sievers EL.

Clin Trials. 2016 Oct;13(5):545-54. doi: 10.1177/1740774516645338. Epub 2016 May 5.

11.

Safety classification of herbal medicines used in pregnancy in a multinational study.

Kennedy DA, Lupattelli A, Koren G, Nordeng H.

BMC Complement Altern Med. 2016 Mar 15;16:102. doi: 10.1186/s12906-016-1079-z.

12.

Potential drivers of virulence evolution in aquaculture.

Kennedy DA, Kurath G, Brito IL, Purcell MK, Read AF, Winton JR, Wargo AR.

Evol Appl. 2016 Jan 11;9(2):344-54. doi: 10.1111/eva.12342. eCollection 2016 Feb.

13.

Transcriptional Profiling of Dibenzo[def,p]chrysene-induced Spleen Atrophy Provides Mechanistic Insights into its Immunotoxicity in MutaMouse.

Chepelev NL, Long AS, Williams A, Kuo B, Gagné R, Kennedy DA, Phillips DH, Arlt VM, White PA, Yauk CL.

Toxicol Sci. 2016 Jan;149(1):251-68. doi: 10.1093/toxsci/kfv232. Epub 2015 Oct 24.

PMID:
26496743
14.

HPLC Measurement of the DNA Oxidation Biomarker, 8-oxo-7,8-dihydro-2'-deoxyguanosine, in Cultured Cells and Animal Tissues.

Chepelev NL, Kennedy DA, Gagné R, White T, Long AS, Yauk CL, White PA.

J Vis Exp. 2015 Aug 1;(102):e52697. doi: 10.3791/52697.

15.

Imperfect Vaccination Can Enhance the Transmission of Highly Virulent Pathogens.

Read AF, Baigent SJ, Powers C, Kgosana LB, Blackwell L, Smith LP, Kennedy DA, Walkden-Brown SW, Nair VK.

PLoS Biol. 2015 Jul 27;13(7):e1002198. doi: 10.1371/journal.pbio.1002198. eCollection 2015 Jul.

16.

An observational study of the temporal and spatial patterns of Marek's-disease-associated leukosis condemnation of young chickens in the United States of America.

Kennedy DA, Dunn JR, Dunn PA, Read AF.

Prev Vet Med. 2015 Jul 1;120(3-4):328-35. doi: 10.1016/j.prevetmed.2015.04.013. Epub 2015 May 8.

17.

Complementary medical health services: a cross sectional descriptive analysis of a Canadian naturopathic teaching clinic.

Kennedy DA, Bernhardt B, Snyder T, Bancu V, Cooley K.

BMC Complement Altern Med. 2015 Feb 28;15:37. doi: 10.1186/s12906-015-0550-6.

18.

Polysaccharide K and Coriolus versicolor extracts for lung cancer: a systematic review.

Fritz H, Kennedy DA, Ishii M, Fergusson D, Fernandes R, Cooley K, Seely D.

Integr Cancer Ther. 2015 May;14(3):201-11. doi: 10.1177/1534735415572883. Epub 2015 Mar 17. Review.

PMID:
25784670
19.

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.

Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, Spitzer G, Palanca-Wessels MC, Kennedy DA, Levine P, Yang J, Bartlett NL.

Blood. 2015 Feb 26;125(9):1394-402. doi: 10.1182/blood-2014-09-598763. Epub 2015 Jan 8.

20.

Pathogen growth in insect hosts: inferring the importance of different mechanisms using stochastic models and response-time data.

Kennedy DA, Dukic V, Dwyer G.

Am Nat. 2014 Sep;184(3):407-23. doi: 10.1086/677308. Epub 2014 Aug 7.

PMID:
25141148
21.

Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.

Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR.

J Clin Oncol. 2014 Oct 1;32(28):3137-43. doi: 10.1200/JCO.2013.54.2456. Epub 2014 Aug 18.

22.

The effect of immunodeficiency on the evolution of virulence: an experimental test with the rodent malaria Plasmodium chabaudi.

Barclay VC, Kennedy DA, Weaver VC, Sim D, Lloyd-Smith JO, Read AF.

Am Nat. 2014 Aug;184 Suppl 1:S47-57. doi: 10.1086/676887. Epub 2014 Jul 15.

PMID:
25061677
23.

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.

Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O'Connor OA, Siddiqi T, Kennedy DA, Oki Y.

Blood. 2014 May 15;123(20):3095-100. doi: 10.1182/blood-2013-12-542142. Epub 2014 Mar 20.

24.

Using quantitative disease dynamics as a tool for guiding response to avian influenza in poultry in the United States of America.

Pepin KM, Spackman E, Brown JD, Pabilonia KL, Garber LP, Weaver JT, Kennedy DA, Patyk KA, Huyvaert KP, Miller RS, Franklin AB, Pedersen K, Bogich TL, Rohani P, Shriner SA, Webb CT, Riley S.

Prev Vet Med. 2014 Mar 1;113(4):376-97. doi: 10.1016/j.prevetmed.2013.11.011. Epub 2013 Dec 1. Review.

25.

Herbal medicine use in pregnancy: results of a multinational study.

Kennedy DA, Lupattelli A, Koren G, Nordeng H.

BMC Complement Altern Med. 2013 Dec 12;13:355. doi: 10.1186/1472-6882-13-355.

26.

Vitamin d: pharmacokinetics and safety when used in conjunction with the pharmaceutical drugs used in cancer patients: a systematic review.

Kennedy DA, Cooley K, Skidmore B, Fritz H, Campbell T, Seely D.

Cancers (Basel). 2013 Mar 11;5(1):255-80. doi: 10.3390/cancers5010255.

27.

Ahead of the curve: next generation estimators of drug resistance in malaria infections.

Mideo N, Kennedy DA, Carlton JM, Bailey JA, Juliano JJ, Read AF.

Trends Parasitol. 2013 Jul;29(7):321-8. doi: 10.1016/j.pt.2013.05.004. Epub 2013 Jun 5.

28.

Black cohosh and breast cancer: a systematic review.

Fritz H, Seely D, McGowan J, Skidmore B, Fernandes R, Kennedy DA, Cooley K, Wong R, Sagar S, Balneaves LG, Fergusson D.

Integr Cancer Ther. 2014 Jan;13(1):12-29. doi: 10.1177/1534735413477191. Epub 2013 Feb 25. Review.

PMID:
23439657
29.

Folate Intake, MTHFR Polymorphisms, and the Risk of Colorectal Cancer: A Systematic Review and Meta-Analysis.

Kennedy DA, Stern SJ, Matok I, Moretti ME, Sarkar M, Adams-Webber T, Koren G.

J Cancer Epidemiol. 2012;2012:952508. doi: 10.1155/2012/952508. Epub 2012 Oct 18.

30.

Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies.

Forero-Torres A, Fanale M, Advani R, Bartlett NL, Rosenblatt JD, Kennedy DA, Younes A.

Oncologist. 2012;17(8):1073-80. doi: 10.1634/theoncologist.2012-0133. Epub 2012 Aug 1.

31.

Lead exposure, gestational hypertension and pre-eclampsia: a systematic review of cause and effect.

Kennedy DA, Woodland C, Koren G.

J Obstet Gynaecol. 2012 Aug;32(6):512-7. doi: 10.3109/01443615.2012.693987. Review.

PMID:
22779950
32.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A.

J Clin Oncol. 2012 Jun 20;30(18):2190-6. doi: 10.1200/JCO.2011.38.0402. Epub 2012 May 21.

PMID:
22614995
33.

Green tea and lung cancer: a systematic review.

Fritz H, Seely D, Kennedy DA, Fernandes R, Cooley K, Fergusson D.

Integr Cancer Ther. 2013 Jan;12(1):7-24. doi: 10.1177/1534735412442378. Epub 2012 Apr 24. Review.

PMID:
22532034
34.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R.

J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26.

35.

Objective assessment of an ionic footbath (IonCleanse): testing its ability to remove potentially toxic elements from the body.

Kennedy DA, Cooley K, Einarson TR, Seely D.

J Environ Public Health. 2012;2012:258968. doi: 10.1155/2012/258968. Epub 2011 Nov 29.

36.

A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies.

Fanale MA, Forero-Torres A, Rosenblatt JD, Advani RH, Franklin AR, Kennedy DA, Han TH, Sievers EL, Bartlett NL.

Clin Cancer Res. 2012 Jan 1;18(1):248-55. doi: 10.1158/1078-0432.CCR-11-1425. Epub 2011 Nov 11.

37.

Synthesis of mutual azo prodrugs of anti-inflammatory agents and peptides facilitated by α-aminoisobutyric acid.

Kennedy DA, Vembu N, Fronczek FR, Devocelle M.

J Org Chem. 2011 Dec 2;76(23):9641-7. doi: 10.1021/jo201358e. Epub 2011 Nov 9.

PMID:
22026631
38.

Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials.

Seely D, Wu P, Fritz H, Kennedy DA, Tsui T, Seely AJ, Mills E.

Integr Cancer Ther. 2012 Dec;11(4):293-303. doi: 10.1177/1534735411425484. Epub 2011 Oct 21. Review.

PMID:
22019490
39.

Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma.

Foyil KV, Kennedy DA, Grove LE, Bartlett NL, Cashen AF.

Leuk Lymphoma. 2012 Mar;53(3):506-7. doi: 10.3109/10428194.2011.614706. Epub 2011 Oct 10. No abstract available.

PMID:
21867368
40.

Folate fortification and survival of children with acute lymphoblastic leukemia.

Kennedy DA, Grupp S, Greenberg M, Koren G.

Paediatr Drugs. 2011 Jun 1;13(3):193-6. doi: 10.2165/11588130-000000000-00000.

PMID:
21366358
41.

Folate intake and the risk of colorectal cancer: a systematic review and meta-analysis.

Kennedy DA, Stern SJ, Moretti M, Matok I, Sarkar M, Nickel C, Koren G.

Cancer Epidemiol. 2011 Feb;35(1):2-10. doi: 10.1016/j.canep.2010.11.004. Epub 2010 Dec 21. Review.

PMID:
21177150
42.

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A.

N Engl J Med. 2010 Nov 4;363(19):1812-21. doi: 10.1056/NEJMoa1002965.

43.

Clinically based evidence of drug-herb interactions: a systematic review.

Kennedy DA, Seely D.

Expert Opin Drug Saf. 2010 Jan;9(1):79-124. doi: 10.1517/14740330903405593. Review.

PMID:
20021292
44.

A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders.

Duvic M, Reddy SA, Pinter-Brown L, Korman NJ, Zic J, Kennedy DA, Lorenz J, Sievers EL, Kim YH.

Clin Cancer Res. 2009 Oct 1;15(19):6217-24. doi: 10.1158/1078-0432.CCR-09-0162. Epub 2009 Sep 29.

45.

Gaol and ship fevers.

Collins CH, Kennedy DA.

Perspect Public Health. 2009 Jul;129(4):163-4. No abstract available.

PMID:
19650550
46.

A comparative review of thermography as a breast cancer screening technique.

Kennedy DA, Lee T, Seely D.

Integr Cancer Ther. 2009 Mar;8(1):9-16. doi: 10.1177/1534735408326171. Review.

PMID:
19223370
47.

Cost effectiveness of natural health products: a systematic review of randomized clinical trials.

Kennedy DA, Hart J, Seely D.

Evid Based Complement Alternat Med. 2009 Sep;6(3):297-304. doi: 10.1093/ecam/nem167. Epub 2007 Dec 5.

48.

Selection criteria for the integrated model of plastic surgery residency.

LaGrasso JR, Kennedy DA, Hoehn JG, Ashruf S, Przybyla AM.

Plast Reconstr Surg. 2008 Mar;121(3):121e-125e. doi: 10.1097/01.prs.0000299456.96822.1b.

PMID:
18317094
49.

In vitro analysis of the herbal compound Essiac.

Seely D, Kennedy DA, Myers SP, Cheras PA, Lin D, Li R, Cattley T, Brent PA, Mills E, Leonard BJ.

Anticancer Res. 2007 Nov-Dec;27(6B):3875-82.

50.

Diversity and relationships of bradyrhizobia from legumes native to eastern North America.

Parker MA, Kennedy DA.

Can J Microbiol. 2006 Dec;52(12):1148-57.

PMID:
17473884

Supplemental Content

Loading ...
Support Center